External beam radiation monotherapy for localized or locally advanced prostate cancer

Japanese Journal of Clinical Oncology

Volumn 33, Issue 2, 2003, Pages 73-77

  Takahashi, Atsushi ^a   Yanase, Masahiro ^a,b   Masumori, Naoya ^a   Sasamura, Hiroto ^a   Oda, Toshiro ^a   Tanaka, Toshiaki ^a   Itoh, Naoki ^a   Tsukamoto, Taiji ^a   Oouchi, Atsushi ^a   Hareyama, Masato ^a   Shirato, Hiroki ^c   Takatsuka, Keiji ^b   Miyao, Noriomi ^d  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SUNAGAWA CITY MEDICAL CENTER   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d Muroran City General Hospital   (Japan)

Author keywords

External beam radiation; Localized or locally advanced prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMISTRY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; ENTEROPATHY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROBABILITY; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RADIATION INJURY; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; URINARY TRACT INJURY; BLOOD; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; JAPAN; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSTATE TUMOR; RADIATION DOSE; RADIOTHERAPY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 0037316869     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg015     Document Type: Article

References (23)

1. Porter AT, Littrup P, Grignon D, Forman, J, Montie JE. Radiotherapy and cryotherapy for prostate cancer. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, editors. Campbell's Urology, 7th ed., vol. 3. Philadelphia: Saunsders 1998;2605-27.
2. Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: Where do we stand? Semin Radiat Oncol 1998;8:107-14.
3. Akakura K, Furuya Y, Suzuki H, Komiya A, Ichikawa T, Igarashi T, et al. External beam radiation monotherapy for prostate cancer. Int J Urol 1999; 6:408-23.
4. Kitamura K, Shirato H, Suzuki K, Shinohara N, Demura T, Harabayashi T, et al. The relationship between technical parameters of external beam radiation therapy and complications for localized prostate cancer. Jpn J Clin Oncol 2000;30:225-9.
5. American Society for Therapeutic Radiology and Oncology. Consensus statement: Guideline for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
6. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. J Am Med Assoc 1999;281:1598-604.
7. Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 1999;86:1557-66.
8. Hanlon AL, Hanks GE. Failure patterns and hazard rates for failure suggest the cure of prostate cancer by external radiation. Urology 2000;55: 725-9.
9. Aref I, Eapen O, Cross P. The relationship between failure and time to nadir in patients treated with external beam therapy for T1-3 prostate carcinoma. Radiother Oncol 1998;48:203-7.
10. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
11. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of the Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-21.
12. Meek AG, Park TL, Oberman B, Wielopolski L. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1990;19: 733-41.
13. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:1850-7.
14. Zagars GK, Pollack A, von Eschenback AC. Prognostic factors for clinically localized prostate cancer. Cancer 1997;79:1370-80.
15. Critz FA, Levinson K, Williams WH, Holladay DA, Holladay CT. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology l997;49:322-6.
16. D'Amico AV, Whittington R, Mallkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 1998;280:969-74.
17. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. Group Protocol 85-31. J Clin Oncol 1992;10:1208-17.
18. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997;44:213-21.
19. Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer; therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 1997;3:78-87.
20. Martinez AA, Gonzalez JA, Chung AK, Kestin LL, Balasubramaniam M, Diokno AC, et al. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged and treated at a single institution. Cancer 2000;88:425-32.
21. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomized trial. Lancet 1999;353:267-72.
22. Michalski JM, Purdy JA, Winter K, Roach M III, Vijayakumar S, Sandler HM, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000;46:391-402.
23. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81.